What The Study Did: This cohort study examines the risk for ocular adverse events (serous retinal detachment, retinal vascular occlusion and ischemic optic neuropathy) among men using phosphodiesterase type 5 inhibitors (erectile dysfunction drugs that are one of the most prescribed classes of medications in the United States).
Authors: Mahyar Etminan, Pharm.D., M.Sc., of the University of British Columbia in Vancouver, Canada, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaophthalmol.2022.0663)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2022.0663?guestAccessKey=405458fb-757d-432d-ab46-acb06db56414&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040722
JAMA Ophthalmology